ReviewESMO gastrointestinal oncology2025
Breath- and blood-based molecular assessment for gastroesophageal cancer.
Review in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Perioperative FLOT chemotherapy for locally advanced esophageal adenocarcinoma: from ESOPEC to daily practice-a retrospective cohort study.Journal of thoracic disease · 2026Article
- Gene amplification in the premalignant stages of non-small cell lung cancer development.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroesophageal cancer remains a significant health care problem characterized by diagnosis at advanced stages, rendering a significant proportion of patients ineligible for curative treatment. Conversely, early diagnosis and treatment of gastroesophageal cancer demonstrates markedly improved outcomes, with 5-year overall survival rates ranging from 83% to 96%. To date, gastroesophageal cancer surveillance primarily focuses on patients with Barrett's esophagus, relying on invasive upper endoscopy. However, despite its high specificity, upper endoscopy demonstrates a suboptimal cancer yield and moderate missed rates, compromising its cost-effectiveness for screening in the general population. Moreover, screening strategies for gastroesophageal cancer are still lacking, in part owing to the invasiveness of current diagnostic methods. To overcome these challenges, innovative minimally invasive technologies have emerged, including metabolomics of exhaled breath, and detection of circulating tumor DNA or proteomics in blood. Promising results from phase I diagnostic trials emphasize the potential of these approaches to advance early detection and monitoring of gastroesophageal cancer. As these methods further refine and consistently demonstrate adequate sensitivity and specificity, they are poised to challenge existing diagnostic modalities. This progress may prompt reconsideration of current one-size-fits-all paradigms, facilitating the evolution toward a patient-tailored management of gastroesophageal cancer. In this article, we review the current minimally invasive breath- and blood-based diagnostic approaches for gastroesophageal cancer, elucidating the underlying biologic basis of identifiable biomarkers. As these approaches will become an integral part of future diagnostic paradigms, understanding the operational mechanisms, strengths, and limitations of these approaches is crucial for optimizing their implementation and interpretability in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.